Literature DB >> 21836532

Antiangiogenic isoforms of vascular endothelial growth factor predominate in subretinal fluid of patients with rhegmatogenous retinal detachment and proliferative vitreoretinopathy.

Lukas J A G Ricker1, Suzanne C Dieudonné, Alfons G H Kessels, Emma S Rennel, Tos T J M Berendschot, Fred Hendrikse, Aize Kijlstra, Ellen C La Heij.   

Abstract

BACKGROUND: In proliferative vitreoretinopathy (PVR), a nonangiogenic eye disease that is characterized by the formation of mainly avascular membranes, vascular endothelial growth factor (VEGF) levels are found to be upregulated. Recently, it was discovered that VEGF is alternatively spliced to form the angiogenic (VEGF xxx) and antiangiogenic (VEGF xxx b) family of isoforms. Previous studies on expression of VEGF in PVR samples have not distinguished between the two families of isoforms.
METHODS: We measured total VEGF and VEGF xxx b levels in subretinal fluid of patients with PVR (n = 10) and in patients with uncomplicated rhegmatogenous retinal detachment (n = 27) using enzyme-linked immunosorbent assay.
RESULTS: : We found total VEGF levels to be 2- to 3-fold elevated in the PVR group as compared with the rhegmatogenous retinal detachment group (P = 0.047). Antiangiogenic VEGF xxx b isoforms predominated (>60% of total VEGF) in the majority of rhegmatogenous retinal detachment and PVR samples investigated, although a wide variability of isoform ratios was observed within both groups.
CONCLUSION: The absence of an increased ratio of VEGF xxx to VEGF xxx b in patients with PVR as compared with patients with uncomplicated rhegmatogenous retinal detachment may explain a lack of blood vessels in PVR membranes. Elevated VEGF levels indicate that this cytokine may play a role in the pathogenesis of PVR that is not related to angiogenesis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 21836532     DOI: 10.1097/IAE.0b013e31821800b9

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  6 in total

1.  Increased intravitreal angiopoietin-2 levels associated with rhegmatogenous retinal detachment.

Authors:  Sirpa Loukovaara; Kaisa Lehti; Alexandra Robciuc; Timo Pessi; Juha M Holopainen; Katri Koli; Ilkka Immonen; Jorma Keski-Oja
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2013-11-12       Impact factor: 3.117

2.  Intrasilicone oil injection of bevacizumab at the end of retinal reattachment surgery for severe proliferative vitreoretinopathy.

Authors:  K Ghasemi Falavarjani; M Hashemi; M Modarres; A Hadavand Khani
Journal:  Eye (Lond)       Date:  2014-02-21       Impact factor: 3.775

3.  Comparison between Vascular Endothelial Growth Factor and Platelet-Derived Growth Factor Levels in Rhegmatogenous Retinal Detachment.

Authors:  Andi Muhammad Ichsan; Dyah Ayu Windy; Habibah Setyawati Muhiddin; Muhammad Nasrum Massi; Itzar Chaidir Islam
Journal:  J Ophthalmol       Date:  2021-12-06       Impact factor: 1.909

Review 4.  Mechanisms of inflammation in proliferative vitreoretinopathy: from bench to bedside.

Authors:  Stavros N Moysidis; Aristomenis Thanos; Demetrios G Vavvas
Journal:  Mediators Inflamm       Date:  2012-09-25       Impact factor: 4.711

5.  Expression of Total Vascular Endothelial Growth Factor and the Anti-angiogenic VEGF 165 b Isoform in the Vitreous of Patients with Retinopathy of Prematurity.

Authors:  Min Zhao; Wan-Kun Xie; Yu-Jing Bai; Lyu-Zhen Huang; Bin Wang; Jian-Hong Liang; Hong Yin; Xiao-Xin Li; Xuan Shi
Journal:  Chin Med J (Engl)       Date:  2015-09-20       Impact factor: 2.628

6.  Intravitreal Injection of Bevacizumab in Primary Vitrectomy to Decrease the Rate of Retinal Redetachment: A Randomized Pilot Study.

Authors:  Adib Tousi; Hossein Hasanpour; Masoud Soheilian
Journal:  J Ophthalmic Vis Res       Date:  2016 Jul-Sep
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.